연구·산업동향 FDA Approves Emergency Use for Multiplex Zika Test The Center for Infection and Immunity (CII) at Columbia University’s Mailman School hasannounced that the U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for the CII-ArboViroPlex rRT-PCR Test, the first multiplex assay that simultaneously tests for the presence of Zika virus, all serotypes of dengue virus, chikungunya virus, and West Nile virus, as well as a host gene that ensures the accuracy of results. Available for immediate use in clinical and research settings, the test was developed by CII scientists and an EUA application was submitted to FDA at the request of the National Institute of Allergy and Infectious Diseases (NIAID), a part of the National Institutes of Health (NIH) for use in its multi-country Zika in Infants and Pregnancy (ZIP) study. DATE : 2017.8.24더보기 New system makes fast, customized antibiotic treatments possible Using nanotechnology, image processing tools and statistical analysis, researchers have developed a system that enables faster diagnostics, earlier and more effective treatment of infectious bacteria, and improved patient recovery times. DATE : 2017.6.29더보기 New antiviral drug inhibits epidemic SARS, MERS and animal coronaviruses A new antiviral drug candidate inhibits a broad range of coronaviruses, including the SARS and MERS coronaviruses, a multi-institutional team of investigators reports. The findings support further development of the drug candidate for treating and preventing current coronavirus infections and potential future epidemic outbreaks. DATE : 2017.6.29더보기 10대 감염병 진단기술의 특허현황을 한 눈에 특허청(청장 최동규)은 ‘2017년 상반기 주의해야 할 10대 감염병’에 대한 ‘진단기술의 특허현황’을 인포그래픽(이하 ‘감염병 진단기술 특허 인포그래픽’)으로 제작하여 발표하였다. DATE : 2017.6.29더보기